Innoforce Pharmaceuticals has opened a new advanced cell and gene therapy development facility in Hangzhou, China. Analytical development (AD) and process development (PD) represents a critical step towards providing services for potential clients in their cell and gene therapy product development to support clinical trials and further commercialization. Innoforce’s development facility further strengthens the company’s capability in analytical development, process characterization, validation, and staff training for a broad range of cell and gene products.
